ERBB2 and neoplasm: Whereas fulvestrant did not completely antagonize the effects of E2 on tumor growth, adding C75 to fulvestrant therapy slightly enhanced the capacity of FVT to inhibit the growth of MCF-7/HER2-18 cells (Figure 5).